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The K650E gain-of-function mutation in the tyrosine
kinase domain of FGF receptor 3 (FGFR3) causes
Thanatophoric Dysplasia type II, a neonatal lethal
congenital dwarfism syndrome, and when acquired
somatically, it contributes to carcinogenesis. In this
report, we determine the crystal structure of the
FGFR3 kinase domain harboring this pathogenic
mutation and show that the mutation introduces a
network of intramolecular hydrogen bonds to stabi-
lize the active-state conformation. In the crystal,
the mutant FGFR3 kinases are caught in the act of
trans-phosphorylation on a kinase insert auto-
phosphorylation site, emphasizing the fact that the
K650E mutation circumvents the requirement for
A-loop tyrosine phosphorylation in kinase activation.
Analysis of this trans-phosphorylation complex
sheds light onto the determinants of tyrosine trans-
phosphorylation specificity. We propose that the
targeted inhibition of this pathogenic FGFR3 kinase
may be achievable by small molecule kinase inhibi-
tors that selectively bind the active-state conforma-
tion of FGFR3 kinase.
INTRODUCTION
Fibroblast growth factor receptor (FGFR) tyrosine kinases
mediate the pleiotropic effects of FGFs in human biology and
pathology. Gain-of-function mutations in the tyrosine kinase
domains of FGFRs underlie a wide array of human develop-
mental disorders and malignancies (Beenken and Mohammadi,
2009; Goriely et al., 2009; Webster and Donoghue, 1997b;
Wilkie, 2005). FGFs act in concert with either heparin sulfate
cofactors or Klotho coreceptors to bind and dimerize the ecto-
domains of FGFRs, bringing the cytoplasmic tyrosine kinase
domains into proper proximity and orientation, which allows
trans-phosphorylation on activation loop (A-loop) tyrosines to
occur (Goetz and Mohammadi, 2013). This event triggers kinaseStructure 21, 1889–activation and causes additional trans-phosphorylation reac-
tions on tyrosines in the kinase C-terminal tail and juxtamem-
brane (JM) region to create specific recruitment sites for sub-
strates, thereby increasing the proximity of substrate to the
kinase and facilitating substrate phosphorylation (Bae et al.,
2009; Chen et al., 2008; Goetz and Mohammadi, 2013; Moham-
madi et al., 1996a).
Crystallographic and nuclear magnetic resonance (NMR)
studies of FGFR kinase domains in the unphosphorylated and
A-loop phosphorylated states, as well as constitutively active
FGFR kinases that harbor pathogenic gain-of-functionmutations
(Bae et al., 2009; Chen et al., 2007, 2013; Mohammadi et al.,
1996a), show that the FGFR kinase is principally regulated
at the protein dynamics level by an autoinhibitory network of
hydrogen bonds in the kinase hinge/interlobe region (termed
‘‘molecular brake’’), which restrains the kinase from transitioning
into the active state (Chen et al., 2007, 2013). Upon A-loop tyro-
sine phosphorylation, the phosphate moiety of the phosphory-
lated A-loop tyrosine makes intramolecular hydrogen bonds
with an RTK-invariant arginine at the N-terminal end of the
A-loop, helping to restructure the A-loop into the active confor-
mation. The change in the conformation of the A-loop is then
allosterically communicated to the kinase hinge region, causing
disengagement of the molecular brake, and hence maximal
kinase activation (Chen et al., 2007, 2013).
In FGFRs, the kinase hinge and A-loop are the two hotspots for
pathogenic gain-of-function mutations (Bellus et al., 1995, 2000;
Kan et al., 2002; Wilkie, 2005). Previously, we explored the
mechanisms for FGFR activation by the pathogenic mutations
at the kinase hinge, which led to the discovery of the autoin-
hibitory molecular brake (Chen et al., 2007). The K650E mutation
in the A-loop of FGFR3 kinase is one of the most activating, and
hence pathogenic mutations (Bellus et al., 2000; Naski et al.,
1996; Webster et al., 1996; Webster and Donoghue, 1997a).
When occurring in the germline, the K650Emutation causes Tha-
natophoric Dysplasia type II, a neonatal lethal dwarfism syn-
drome (Tavormina et al., 1995;Wilcox et al., 1998).If acquired so-
matically, it contributes to the progression of multiple myeloma,
bladder cancer and benign skin tumors (Cappellen et al., 1999;
Chesi et al., 1997; Logie´ et al., 2005).
There is a wealth of literature on the molecular mechanisms by
which the hyperactive K650E mutant reduces proliferation of1896, October 8, 2013 ª2013 Elsevier Ltd All rights reserved 1889
Figure 1. The Pathogenic K650E Mutation
Drives the FGFR3 Kinase into the Active
Conformation
(A) Ribbon diagrams of the FGFR3KK650E struc-
ture. b strands and a helices are colored cyan and
green, respectively. The A-loop, catalytic loop,
nucleotide-binding loop, kinase insert, and kinase
hinge are colored magenta, orange, smudge,
wheat, and yellow, respectively. In all of the fig-
ures, the ATP analog (AMP-PCP) and magnesium
ions are rendered as sticks and blue spheres,
respectively.
(B) Close-up view of the catalytically critical salt
bridge between K508 and E525 in the kinase
N-lobe important for ATP coordination and
hydrolysis.
(C) The carboxylate group of E650 introduces a
network of intramolecular hydrogen bonds that
tether the flexible A-loop to the rigid core of
the C-lobe, thereby stabilizing the active-
state conformation of the A-loop. Side chains
of selected residues are shown as sticks.
Atom colorings in this figure and the follow-
ing figures are as follows: oxygens in red, nitro-
gens in blue, and coloring for carbons follow
the coloring scheme of the specific region of the kinase to which they belong. The mutant residue E650 and kinase insert tyrosine Y577 are
labeled in red; other residues are labeled in black. The hydrogen bonds are shown as black dashed lines.
See also Figures S1–S3.
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Structure of a Pathogenic FGFR3K Mutantchondrocytes, causing them to prematurely enter into hyper-
trophic differentiation in the developing cartilage tissue. The
effects of the K650E mutation on FGFR activation, maturation/
trafficking, and downstream signaling pathways have been
extensively studied (Foldynova-Trantirkova et al., 2012; Guo
et al., 2008). Webster and colleagues showed that the A-loop
tyrosines are dispensable for the constitutive activity of the
K650E FGFR3 mutant, implying that K650E mutation activates
the kinase in an A-loop phosphorylation-independent fashion
(Webster et al., 1996). Hence, it was proposed that this patho-
genic mutation mimics the action of A-loop tyrosine phosphory-
lation to activate the kinase (Webster et al., 1996). The molecular
mechanism by which this mutation imparts constitutive activa-
tion upon FGFR3 kinase is perplexing, however, because in
accordance with the crystal structures of A-loop phosphorylated
FGFR1 and FGFR2 kinases, the corresponding lysine residues,
namely, K656 and K659, make intramolecular hydrogen bonds
with the phosphatemoiety of the phosphorylated A-loop tyrosine
and residues in the A-loop that actually help supporting the
active A-loop conformation (Bae et al., 2010; Chen et al.,
2007). Lievens and Liboi showed that the K650Emutation affects
receptor maturation and that the constitutively active mutant ac-
cumulates as a mannose-rich and phosphorylated form in the
endoplasmic reticulum, where it signals through activating
STAT1 and Src (Lievens and Liboi, 2003). Using a neurite
outgrowth differentiation assay in PC12 cells as readout, Now-
roozi and colleagues suggested that activation of STAT1 and 3
may not be required for the K650Emutant to induce hypertrophic
differentiation of the growth plate (Nowroozi et al., 2005). Agazie
and colleagues showed that the K650E mutant requires SHP2 to
induce oncogenic transformation of cells (Agazie et al., 2003).
The importance of elucidating the molecular mechanism by
which the K650E mutation confers gain-of-function on FGFR31890 Structure 21, 1889–1896, October 8, 2013 ª2013 Elsevier Ltd Akinase is 2-fold; first, it may provide new insight into the physio-
logical mechanisms of FGFR kinase regulation, and second, it
may facilitate the rational design of small molecule inhibitors
that can specifically silence the hyperactivity of this pathogenic
FGFR3 mutant. Here, we report the crystal structure of FGFR3
kinase that harbors the K650E mutation. The structure shows
that the mutation functionally mimics the action of A-loop phos-
phorylation in activating the kinase by introducing a network of
hydrogen bonds that stabilize the active-state conformation of
the A-loop. Moreover, the structure provides a snapshot of two
FGFR kinase molecules engaged in the act of trans-phosphory-
lation on the kinase insert tyrosine. Comparison of this trans-
phosphorylation complex with a previously reported kinase
trans-phosphorylation complex involving the C-terminal tail tyro-
sine (Chen et al., 2008) provides valuable insights into themolec-
ular mechanism that controls trans-phosphorylation specificity.
Based on our structural data, targeted inhibition of this patho-
genic FGFR3 kinase can be achieved by small molecule kinase
inhibitors that selectively bind the active-state conformation of
FGFR3 kinase.
RESULTS
To elucidate the molecular basis by which the pathogenic K650E
mutation imparts constitutive activation upon FGFR3 kinase
in human diseases, we solved the crystal structure of the
FGFR3KK650E mutant in complex with AMP-PCP, a nonhydrolyz-
able ATP analog, at 2.35 A˚ resolution (Figure 1A). Data collection
and structure refinement statistics are given in Table 1. The
refined model consists of residues L459 to T755, one AMP-
PCP molecule, two Mg2+ ions, and 128 water molecules.
FGFR3KK650E exhibits the canonical two-lobe architecture of
protein kinases with the smaller N-lobe comprising a twistedll rights reserved
Table 1. X-Ray Data Collection and Refinement Statistics
Construct FGFR3KK650E
Data Collection
Resolution (A˚) 50–2.35 (2.39–2.35)a
Space group P212121
Unit cell parameters (A˚, ) a = 54.226 a = 90.00
b = 61.427 b = 90.00
c = 100.666 g = 90.00
Content of the asymmetric unit 1
No. of measured reflections 67,586
No. of unique reflections 14,385
Data redundancy 4.7
Data completeness (%) 97.0 (61.1)
Rsym (%)
b 7.1 (24.3)
I/sig 32.4
Refinement
R factor/R free 17.92/22.05
No. of protein atoms 2,322
No. of solvent atoms 128
No. of nonprotein/solvent atoms 33
Rmsd bond length (A˚) 0.003
Rmsd bond angle () 0.776
PDB ID 4K33
aThe numbers in parentheses refer to the highest resolution shell.
bRsym=
PjI hIij=P I, where I is the observed intensity of a reflection,
and hIi is the average intensity of all of the symmetry-related reflections.
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Structure of a Pathogenic FGFR3K Mutantfive-stranded b sheet and the a helix C, and the larger C-lobe
consists mainly of a helices (Figure 1). The ATP analog AMP-
PCP is tucked snugly in the ATP-binding cleft between the two
lobes, where it makes numerous hydrogen bonds and hydropho-
bic contacts with residues in both lobes as well as in the kinase
hinge region (Figure 1). The entire A-loop, bracketed between
635DFG and LPV658 motifs, is ordered, including the two tyrosine
residues (Y647 and Y648), the phosphorylation of which is
necessary for kinase activation. Most of the loop between the
aD and aE helices, better known as the kinase insert region, is
ordered as well (Figure 1A). The ordering of this highly flexible
loop is attributable to the fact that the autophosphorylation site
Y577 from this loop inserts into the catalytic pocket of a neigh-
boring kinase in the crystal, thereby forming an enzyme-sub-
strate trans-phosphorylation complex.
The K650E Mutation Confers Gain-of-Function by
Stabilizing the Active Conformation of the Kinase
A-Loop
Superimposition of the FGFR3KK650E structure onto the struc-
tures of unphosphorylated (low activity state) and A-loop phos-
phorylated (active state) FGFR1 (Bae et al., 2009; Mohammadi
et al., 1996a) and FGFR2 (Chen et al., 2007, 2008) kinases unam-
biguously shows that FGFR3KK650E is in the active-state confor-
mation (Figure 1B; Figure S1 available online). The A-loop of
FGFR3KK650E superimposes onto that of phosphorylated
FGFR1 and FGFR2 kinases with root-mean-square deviations
(rmsd) of 0.81 and 1.2 A˚, respectively, and features the b strandsStructure 21, 1889–10 and 12 that are characteristics of the activated kinases (Fig-
ure 1). A network of intramolecular hydrogen bonds introduced
by the K650E mutation facilitates and stabilizes the active-state
conformation of the A-loop in the FGFR3KK650E structure (Fig-
ure 1B). Specifically, the carboxylate group of E650 makes five
hydrogen bonds: two with R616 in the catalytic loop, one each
with the backbone amides of T651 and T652, and one with
Y648 within the A-loop (Figures 1B and S2). The latter hydrogen
bond helps position the side chain of Y648 into a nearly identical
location as that of the corresponding phosphorylated tyrosine
residue in the A-loop phosphorylated wild-type (WT) FGFR1
and FGFR2 kinases (Figure S1). The hydroxyl group of Y648 in
FGFR3KK650E makes an intramolecular hydrogen bond with
R640 at the N-terminal end of the A-loop, which is reminiscent
of the hydrogen bonds that the phosphate moiety of the phos-
phorylated A-loop tyrosine makes with the invariant A-loop argi-
nine (Figures 1B and S2). This hydrogen bond likely also contrib-
utes to the active-state conformation of the A-loop.
As in the crystal structures of A-loop phosphorylated, acti-
vated FGFR1 and FGFR2 kinases (Bae et al., 2009; Chen et al.,
2007), the autoinhibitory molecular brake at the kinase hinge/
interlobe region of FGFR3KK650E is disengaged, providing further
evidence that the mutation drives the kinase into the active state
(Figure S3). The active-state conformation of FGFR3KK650E is
also apparent by the formation of a catalytically important salt
bridge between the invariant E525 in the aC helix and K508 in
the b3 strand of the kinase N-lobe (Figure 1C). This salt bridge
primes K508 for hydrogen bonding with the a and b phosphate
groups of AMP-PCP (Figure 1C). Analysis of crystal packing con-
tacts provides additional strong evidence that the mutated
FGFR3 kinase has adopted the active-state conformation. In
the crystal, FGFR3KK650E molecules are trapped in the act of
trans-phosphorylation, whereby one kinase molecule acts as
the enzyme, while the other serves as the substrate, offering a
phosphorylatable tyrosine residue from the kinase insert region
(Y577) (Figure 2). The hydroxyl moiety Y577 of the substrate-
acting kinase engages in two short-range hydrogen bonds with
the catalytic base D617 of the enzyme-acting kinase and is about
5 A˚ away from the g-phosphate of the ATP analog AMP-PCP,
indicating that Y577 from the substrate-acting kinase is poised
for deprotonation and phosphorylation by the enzyme-acting
kinase (Figure 2). Given the fact that substrate binding is
strictly dependent on kinase activation (Hubbard and Till,
2000), this observation lends further support for the fact that
the K650E mutation has forced the FGFR3 kinase into the active
state. Taken together, these structural findings unambiguously
demonstrate that the pathogenic K650E mutation confers gain-
of-function by functionally mimicking the action of A-loop tyro-
sine phosphorylation in stabilizing the active-state conformation
of the A-loop.
The K650E Mutation Activates FGFR3 Kinase
Independent of A-Loop Tyrosine Phosphorylation
To functionally validate our structural finding that the K650E
mutation circumvents the requirement for A-loop tyrosine phos-
phorylation for FGFR3 kinase activation, we next compared the
kinase activity of FGFR3KK650E with that of FGFR3KK650E
harboring Y647F or Y648F single mutations or the Y647F/
Y648F double mutation in vitro (Figures 3A–3E). As expected,1896, October 8, 2013 ª2013 Elsevier Ltd All rights reserved 1891
Figure 2. Crystallographic Snapshot of the Kinase Insert trans-
Phosphorylation Reaction
(A) The substrate-acting kinase (in cyan) interacts with both N- and C-lobe of
the enzyme-acting kinase (in green) during the trans-phosphorylation on Y577.
(B) A detailed view of the interface formed between the enzyme-acting and
substrate-acting kinases. The interacting residues are shown as sticks and
labeled in black for the enzyme-acting kinase and in blue for the substrate-
acting kinase. The kinase insert region is colored wheat, and the side chain of
the Y577 residue is shown as yellow sticks and labeled in red. The hydrogen
bonds are shown as black dashed lines. Atom coloring is as in Figure 1.
See also Figure S1.
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Structure of a Pathogenic FGFR3K MutantFGFR3KK650E exhibited greater activity than wild-type FGFR3K
(FGFR3KWT) at every time point examined, with the greatest
difference (over 20-fold) seen at 20 s, the earliest measured
time point (Figure 3F). The difference in activity between
FGFR3KK650E and FGFR3KWT tapered off at later time points,
however. This is expected, as A-loop tyrosine phosphorylation
takes place over time, amplifying the catalytic activity of
FGFR3KWT. The activity of the FGFR3KK650E mutants in which
one or both A-loop tyrosine residues has been replaced with
phenylalanine remains comparable to that of the parent
FGFR3KK650E molecule (Figure 3F), corroborating that kinase
activation by the K650E mutation occurs independent of
A-loop tyrosine phosphorylation. Our data are consistent with
the previously published data by Webster and colleagues
showed that the A-loop tyrosines are dispensable for the consti-
tutive activity of the K650E FGFR3 mutant, implying that K650E
mutation activates the kinase in an A-loop phosphorylation-
independent fashion (Webster et al., 1996). Notably, unlike
FGFR3KWT, the activity of FGFR3KK650E did not increase sig-
nificantly over time (Figure 3F), further substantiating that the
K650Emutation activates the kinase independent of A-loop tyro-
sine phosphorylation. Taken together, these biochemical data
support the structural finding that the K650E mutation confers
constitutive activation by essentially mimicking the action of
A-loop tyrosine phosphorylation in stabilizing the active-state
conformation of the kinase.1892 Structure 21, 1889–1896, October 8, 2013 ª2013 Elsevier Ltd AStructural Basis for Specificity of Tyrosine
trans-Phosphorylation in FGFR3 Kinase
The crystal structure of FGFR3KK650E depicts, as already
mentioned, a snapshot of a trans-phosphorylation reaction on
the kinase insert tyrosine residue Y577. We previously reported
the crystal structure of FGFR2 kinases caught in the act
of trans-phosphorylation on the FGFR-invariant C-terminal tail
tyrosine (Chen et al., 2008). Comparison of the two kinase
trans-phosphorylation complexes provides important insights
into the molecular determinants of specificity of kinase tyro-
sine trans-phosphorylation. Similar to the C-terminal tail tyrosine
trans-phosphorylation complex, the kinase insert tyrosine trans-
phosphorylation complex is also asymmetric, wherein the
C-lobe of the substrate-acting kinase engages both the N- and
C-lobe of the enzyme-acting kinase (Figure 2). The enzyme-sub-
strate interface can be roughly divided into a proximal and a
distal site, with the former in the vicinity of the catalytic cleft of
the enzyme-acting kinase and the latter remote from the catalytic
cleft of the enzyme-acting kinase.
At the proximal interface, several contacts in the kinase insert
tyrosine trans-phosphorylation complex (Figure 4A) diverge from
those observed in the C-terminal tail tyrosine trans-phosphoryla-
tion complex (Figure 4B). Notably, in stark contrast to the C-ter-
minal tail tyrosine trans-phosphorylation complex, where the
P+1 pocket of the enzyme plays an important role in providing
specificity at the proximal enzyme-substrate interface (Fig-
ure 4B), this pocket is not utilized in the kinase insert tyrosine
trans-phosphorylation complex. Instead, proximal specificity in
this complex is primarily achieved by R655 from the A-loop of
the enzyme-acting kinase. The guanidinium moiety of R655
stacks against the phenyl ring of Y577 via a p-cation interaction
and also forms a hydrogen bond with the backbone carbonyl
oxygen of P573 in the kinase insert of the substrate-acting kinase
(Figure 4A).
At the distal interface, the contacts in the kinase insert tyrosine
trans-phosphorylation complex are completely different from
those observed in the C-terminal tail tyrosine trans-phosphoryla-
tion complex. The main specific contacts in the distal site of the
kinase insert tyrosine trans-phosphorylation complex are two
hydrogen bonds between R571 (from the N-terminal end of the
kinase insert of the substrate-acting kinase) and the backbone
carbonyl oxygen atom of D513 in the loop between b3 strand
and aC helix of the enzyme-acting kinase (Figure 4A). All of the
remaining interactions at this distal contact site are of van der
Waals nature with the most notable ones being the contacts
between F483 from the nucleotide-binding loop of the enzyme-
acting kinase and R571 of the substrate-acting kinase.
To functionally probe the observed mode of trans-phosphory-
lation specificity on the kinase insert tyrosine in the FGFR3KK650E
crystal, we studied the impact of mutating R571 to alanine on
phosphorylation of the kinase insert tyrosine Y577. Consistent
with the structural data, the R571A mutation drastically impaired
phosphorylation of the kinase insert tyrosine (Y577) but had only
a minor effect on the phosphorylation of the C-terminal tail
tyrosine (Y760) (Figure 4D). As expected based on our previous
crystal structure of the C-terminal tail tyrosine trans-phosphory-
lation complex (Chen et al., 2008), substitution of L761, which
engages the P+1 pocket of the enzyme, with alanine caused a
major decrease in the kinase C-terminal tail tyrosinell rights reserved
Figure 3. The Pathogenic K650E Mutation Circumvents the Requirement for A-Loop Tyrosine Phosphorylation for FGFR3 Kinase Activation
(A–E) The substrate phosphorylation activities of FGFR3KWT, FGFR3KK650E, and its A-loop tyrosine mutant derivatives (FGFR3KK650E/Y647F, FGFR3KK650E/Y648F,
and FGFR3KK650E/Y647F/Y648F) were compared using native-PAGE (upper panel) coupled with time-resolved MALDI Q-TOF MS (lower panel).
(F) The percentage of at least one site phosphorylation on the substrate was quantitated using the peak intensity data generated by mass spectrometry. For the
sake of accuracy, only the MS data of the early time points (20, 40, and 60 s), which are in the linear phase of the kinase assay, were processed and presented.
Structure
Structure of a Pathogenic FGFR3K Mutantphosphorylation but had little impact on phosphorylation of the
kinase insert tyrosine (Figure 4E).
DISCUSSION
In this study we elucidated the molecular mechanism by which
the pathogenic K650E mutation in FGFR3, which underlies a
lethal skeletal dysplasia in humans, confers gain-of-function on
FGFR3. Our data unambiguously demonstrate that the K650E
mutation mimics the action of A-loop tyrosine phosphorylation
to cause ligand-independent activation of FGFR3. It should be
noted that enzymes, in general, and tyrosine kinases, in partic-
ular, are intrinsically dynamic protein moieties, and in fact the
catalytic turnover rate of enzymes is strongly correlated with
magnitude and timescales of internal motions that enzymes
undergo (Eisenmesser et al., 2005; Villali and Kern, 2010). Using
X-ray crystallography and NMR spectroscopy, we have recently
shown that FGFR kinases swing between an inhibited state,
which is conformationally rigid and stable, and an active state,
which is conformationally dynamic and hence inhomogeneous
(Chen et al., 2013). The unphosphorylated wild-type FGFR
kinase can sample the active state albeit with low frequency
and hence predominately populates the inhibited state. Patho-
genic mutations, such as the K650E mutation, introduce intra-
molecular contacts that facilitate the ability of the kinase to adoptStructure 21, 1889–and remain longer in the active state, thereby increasing the
population of kinase molecules in the active state (Chen et al.,
2013). In other words, the crystallographically fixed intramolecu-
lar hydrogen bonding contacts introduced by the mutation are
dynamic in solution, and the FGFR3KK650E pathogenic kinase
also oscillates between inhibited and active states with the
equilibrium being skewed toward the active state.
Comparison of the kinase insert tyrosine trans-phosphoryla-
tion complex in the FGFR3KK650E crystal with the FGFR2 kinase
C-terminal tail tyrosine trans-phosphorylation complex (Chen
et al., 2008) shows that kinase trans-phosphorylation entails a
great degree of sequence specificity and structural complemen-
tarities. It remains to be determined whether Y577 of FGFR3 is
phosphorylated in living cells. However, the equivalent tyrosine
in FGFR1, Y583, is a bona fide in vivo phosphorylation site
(Mohammadi et al., 1996b) and is also a secondmajor autophos-
phorylation site in vitro (Furdui et al., 2006). Y577 is readily phos-
phorylated in vitro, both in the wild-type and in the K650Emutant
FGFR3 kinases. Based on these observations, we surmise that
Y577 undergoes phosphorylation in vivo as well. Future efforts
should be directed toward elucidating the structural basis for
trans-phosphorylation on the A-loop tyrosines, the earliest
trans-phosphorylation event necessary for kinase activation. A
full comprehension of the molecular details of FGFR trans-phos-
phorylation reactions will be essential to understanding FGFR1896, October 8, 2013 ª2013 Elsevier Ltd All rights reserved 1893
Figure 4. Structural Determinants of Tyrosine trans-Phosphorylation Specificity in FGFR Kinases
(A) Contacts between R571 of substrate and F483 of enzyme at the distal site mediate FGFR3 tyrosine trans-phosphorylation specificity on the kinase insert
tyrosine Y577. Van der Waals surfaces of R571 and F483 are shown in mesh to emphasize their contacts. Likewise, meshed surfaces are used to indicate the
p-cation interaction between the guanidinium moiety of R655 and the phenyl ring of Y577.
(B) Based on the crystal structure of FGFR2 kinases trapped in the act of trans-phosphorylation on C-terminal tail tyrosine, the hydrophobic contacts between
L761 of substrate and the P+1 pocket of the enzyme are critical for tyrosine trans-phosphorylation specificity on the C-terminal tail tyrosine Y760 in FGFR3. To
highlight the hydrophobic contacts between the substrate and the enzyme at the P+1 pocket, the molecular surfaces of P+1 and P+3 residues (L761 and L763) of
the substrate and residues in the P+1 pocket of the enzyme (L656, V700, and F704) are shown. Enzyme-acting kinases in both trans-phosphorylation complexes
are colored green. Substrate-acting kinases are colored cyan and salmon in kinase insert and C-terminal tail tyrosine trans-phosphorylation complexes,
respectively.
(C–E) Analysis of autophosphorylation by mass spectrometry corroborates the importance of R571 and L761 in substrate recognition in the kinase insert and
C-terminal tail tyrosine trans-phosphorylation. The R571A mutation diminishes trans-phosphorylation on the kinase insert tyrosine Y577 without a major impact
on the C-terminal tail tyrosine phosphorylation (D). The L761A mutation (equivalent to L770A in FGFR2) impairs the trans-phosphorylation of the C-terminal tail
tyrosine Y760 (E).
Structure
Structure of a Pathogenic FGFR3K Mutantsignaling and devising novel strategies for targeted modulation
of FGF signaling for therapeutic purposes.
EXPERIMENTAL PROCEDURES
Please refer to the Supplemental Experimental Procedures for full details.
Protein Expression and Purification
The human FGFR3 kinase domains FGFR3K450-758 and FGFR3K429-768,
including their mutated forms, and the C-terminal tail peptide of FGFR2 kinase1894 Structure 21, 1889–1896, October 8, 2013 ª2013 Elsevier Ltd A(FGFR2K761-821) were all expressed using pET bacterial expression vectors
with an N-terminal 6XHis-tag to aid in protein purification.
Crystallization and Structure Determination
Crystals of the FGFR3KK650E protein in complex with the ATP-analog (AMP-
PCP) were grown by vapor diffusion at 20C using crystallization buffer
composed of 0.1 M HEPES (pH 7.5), 20% (w/v) PEG 4000, and 4% (v/v)
(±)-1,3 Butanediol. Diffraction data were processed using the HKL2000 suite
(Otwinowski and Minor, 1997), and the structure was solved by the molecular
replacement program AMoRe (Navaza, 1994), using the crystal structure of
FGFR2 kinase that harbors the K659N mutation (Protein Data Bank [PDB] IDll rights reserved
Structure
Structure of a Pathogenic FGFR3K Mutantcode 2PVY) (Chen et al., 2007) as the search model. Model building was
carried out using O (Jones et al., 1991), and at later stages Coot (Emsley
and Cowtan, 2004) was used, and refinement was completed using PHENIX
(Adams et al., 2002).
Dissection of the Role of A-Loop Tyrosine Phosphorylation
in Gain-of-Function by the K650E Mutation Using Peptide
Substrate Phosphorylation
Peptide substrate phosphorylation activities of wild-type and mutated FGFR3
kinases (FGFR3KWT, FGFR3KK650E, FGFR3KK650E/Y647F, FGFR3KK650E/Y648F,
and FGFR3KK650E/Y647F/Y648F) were analyzed by MALDI-TOF MS (Bruker Auto-
flex MALDI-TOF, Bruker Daltonics) in positive ion linear mode.
Analysis of the Specificity of Tyrosine trans-Phosphorylation
The trans-phosphorylation on kinase insert and C-terminal tail tyrosines in
wild-type and mutated FGFR3 kinases (FGFR3K440-778, FGFR3K440-778/R571A,
FGFR3K440-778/R655A, and FGFR3K440-778/L761A) were analyzed by LTQ Orbi-
trap (Thermo Electron) liquid chromatography-tandem mass spectrometry.
ACCESSION NUMBERS
The coordinates and structure factors for the FGFR3KK650E structure have
been deposited in the Protein Data Bank under the accession number 4K33.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and three figures and can be found with this article online at http://dx.doi.
org/10.1016/j.str.2013.07.017.
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